London, UK, September 15, 2026
GSK has announced an agreement to acquire a potential best-in-class T-cell engager (TCE) from Chimagen Biosciences, strengthening its multiple myeloma pipeline and expanding its portfolio of targeted immunotherapies. The transaction centers on CM336, an investigational BCMA×CD3 bispecific T-cell engager designed to direct a patient’s T cells toward multiple myeloma cells expressing B-cell maturation antigen (BCMA). The acquisition represents another strategic move by GSK to strengthen its position in hematologic malignancies and advance next-generation immune-based treatments for patients with multiple myeloma. CM336 is currently being evaluated in clinical development, with the program expected to become part of GSK’s broader oncology pipeline following completion of the transaction.
GSK Expands Multiple Myeloma Pipeline
Multiple myeloma is a blood cancer affecting plasma cells and remains a major area of unmet medical need despite significant progress in treatment. GSK has established an important presence in multiple myeloma through its BCMA-targeted therapy belantamab mafodotin, and the addition of a T-cell engager could further expand the company’s ability to target the disease through complementary mechanisms. The acquisition of CM336 is therefore aligned with GSK’s strategy of developing differentiated medicines for hematologic cancers where new therapeutic approaches may improve patient outcomes. CM336 is designed to bind simultaneously to BCMA on malignant plasma cells and CD3 on T cells. By bringing the immune cells into close proximity with cancer cells, the TCE is intended to activate T cells and promote the destruction of BCMA-expressing myeloma cells. This mechanism represents a targeted form of immune-mediated cancer treatment and builds on the growing clinical importance of T-cell-engaging therapies in hematologic malignancies. GSK believes the program has the potential to become a best-in-class treatment option within the evolving multiple-myeloma therapeutic landscape.
Chimagen’s CM336 Targets BCMA and CD3
The acquisition provides GSK with access to Chimagen’s CM336 development program, including global rights to the investigational therapy. The candidate has been developed using Chimagen’s T-cell engager technology and is being evaluated in patients with multiple myeloma. The company has generated clinical data intended to support continued development of the program and its potential positioning in different stages of the disease. A major scientific advantage of the BCMA×CD3 approach is its ability to leverage the patient’s own immune system to attack cancer cells. BCMA is highly expressed on malignant plasma cells and has consequently become an important target in multiple myeloma drug development. CD3, meanwhile, is present on T cells, allowing a bispecific T-cell engager to form a molecular bridge between the immune cell and the tumor cell. This targeted interaction can trigger T-cell activation and subsequent cancer-cell killing. The development of T-cell engagers has become an increasingly important area of biopharmaceutical innovation, particularly in blood cancers. The acquisition allows GSK to build on this scientific momentum while adding another potentially differentiated BCMA-targeted asset to its oncology portfolio.
Advertisement
Strategic Acquisition Strengthens GSK Oncology
The agreement with Chimagen demonstrates GSK’s continued focus on business development and external innovation to strengthen its pipeline. Acquiring promising clinical-stage assets can provide pharmaceutical companies with access to technologies and therapeutic candidates that complement internally developed programs while potentially accelerating the availability of new treatment options. For GSK, CM336 adds a new modality to its multiple-myeloma strategy and could provide opportunities for future development in combination with other therapies. The company’s broader oncology strategy includes targeted therapies and immuno-oncology approaches designed to address cancers with significant unmet needs. The transaction remains subject to customary closing conditions, including applicable regulatory requirements. Following completion, GSK will assume responsibility for advancing the CM336 program and determining its future clinical-development strategy. The announcement highlights the continuing competition among major pharmaceutical companies to secure next-generation cancer immunotherapies. With T-cell engagers demonstrating growing potential in hematologic malignancies, assets targeting BCMA and other tumor-associated antigens remain attractive opportunities for pharmaceutical investment and pipeline expansion. GSK’s agreement with Chimagen consequently represents both a significant corporate-development milestone and an important development in the search for improved therapies for patients with multiple myeloma.
Source: GSK, Chimagen Biosciences press release
